SG10201500124VA - Methods and Compositions for Treating Cancer - Google Patents

Methods and Compositions for Treating Cancer

Info

Publication number
SG10201500124VA
SG10201500124VA SG10201500124VA SG10201500124VA SG10201500124VA SG 10201500124V A SG10201500124V A SG 10201500124VA SG 10201500124V A SG10201500124V A SG 10201500124VA SG 10201500124V A SG10201500124V A SG 10201500124VA SG 10201500124V A SG10201500124V A SG 10201500124VA
Authority
SG
Singapore
Prior art keywords
compositions
methods
treating cancer
cancer
treating
Prior art date
Application number
SG10201500124VA
Inventor
Yu Qiang
Tan Jing
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Priority to SG10201500124VA priority Critical patent/SG10201500124VA/en
Publication of SG10201500124VA publication Critical patent/SG10201500124VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
SG10201500124VA 2010-01-08 2011-01-10 Methods and Compositions for Treating Cancer SG10201500124VA (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SG10201500124VA SG10201500124VA (en) 2010-01-08 2011-01-10 Methods and Compositions for Treating Cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG2010001147 2010-01-08
SG2010016293 2010-03-04
SG10201500124VA SG10201500124VA (en) 2010-01-08 2011-01-10 Methods and Compositions for Treating Cancer

Publications (1)

Publication Number Publication Date
SG10201500124VA true SG10201500124VA (en) 2015-03-30

Family

ID=55167913

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201500124VA SG10201500124VA (en) 2010-01-08 2011-01-10 Methods and Compositions for Treating Cancer
SG2012049342A SG182347A1 (en) 2010-01-08 2011-01-10 Methods and compositions for treating cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2012049342A SG182347A1 (en) 2010-01-08 2011-01-10 Methods and compositions for treating cancer

Country Status (5)

Country Link
US (1) US9249466B2 (en)
EP (1) EP2521913A4 (en)
CN (1) CN102792160B (en)
SG (2) SG10201500124VA (en)
WO (1) WO2011084108A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120245044A1 (en) * 2011-03-25 2012-09-27 Translational Genomics Research Institute Methods of determining chemotherapy response in cancer
WO2014046617A1 (en) * 2012-09-19 2014-03-27 Agency For Science, Technology And Research Compositions and methods for treating cancer
US20150330984A1 (en) * 2012-12-06 2015-11-19 Dana-Farber Cancer Institute, Inc. Metabolomic profiling defines oncogenes driving prostate tumors
EP2865757A1 (en) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the PDK1 gene.
EP2881472A1 (en) 2013-12-09 2015-06-10 Université Pierre et Marie Curie (Paris 6) A method of predicting a response to an anti-tumor treatment
ES2812753T3 (en) * 2014-03-31 2021-03-18 Mayo Found Medical Education & Res Detection of colorectal neoplasm
CA2959347C (en) 2014-08-25 2023-03-07 Salk Institute For Biological Studies Ulk1 inhibitors and methods using same
WO2016090365A1 (en) * 2014-12-05 2016-06-09 Dessain Scott Kendall Pdk1 binding molecules and uses thereof
US9607375B2 (en) * 2015-06-03 2017-03-28 Eileen B. Gallagher Biological data annotation and visualization
US10672505B2 (en) 2015-06-03 2020-06-02 General Electric Company Biological data annotation and visualization
US9953133B2 (en) 2015-06-03 2018-04-24 General Electric Company Biological data annotation and visualization
US10351609B2 (en) * 2016-12-12 2019-07-16 Medical Diagnostic Laboratories, Llc Cell-based assay for determining mTOR activity
WO2019051090A2 (en) * 2017-09-06 2019-03-14 Marshall University Research Corporation METHODS FOR DETECTING Na/K-ATPASE-MEDIATED SRC SIGNALING FOR DIAGNOSIS AND PROGNOSIS OF CANCER
CN116064806B (en) * 2022-10-19 2023-09-22 常州国药医学检验实验室有限公司 Composition for evaluating early gastric cancer lymph node metastasis risk and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2480635A1 (en) * 2002-03-28 2003-10-09 Allen D. Delaney Cancer associated protein kinases and their uses
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
JPWO2005007846A1 (en) 2003-04-25 2006-08-31 財団法人癌研究会 Method for determining the sensitivity of tumor cells to anticancer agents
DE102005037500A1 (en) 2005-08-09 2007-02-15 Merck Patent Gmbh Immobilizable N-heterocyclic carbene-metal complexes with alkoxysilyl groups
EP1946120A2 (en) 2005-10-18 2008-07-23 George Mason Intellectual Properties, Inc. Mtor pathway theranostic
CN101541783B (en) * 2006-06-30 2014-10-01 苏尼西斯制药有限公司 pyridinonyl PDK1 inhibitors
US8455477B2 (en) * 2008-08-05 2013-06-04 Merck Sharp & Dohme Corp. Therapeutic compounds
GB2488028A (en) 2011-02-09 2012-08-15 Astrazeneca Ab mTOR mutants as biomarkers for mTOR inhibitor treatment

Also Published As

Publication number Publication date
CN102792160B (en) 2015-08-19
SG182347A1 (en) 2012-08-30
US9249466B2 (en) 2016-02-02
WO2011084108A1 (en) 2011-07-14
US20130123328A1 (en) 2013-05-16
EP2521913A1 (en) 2012-11-14
CN102792160A (en) 2012-11-21
EP2521913A4 (en) 2013-05-15

Similar Documents

Publication Publication Date Title
HK1209798A1 (en) Compositions and methods for treating cancer
IL227429A0 (en) Compositions and methods for treating cancer
EP2755482A4 (en) Compositions and methods for treating cancer
IL218987A0 (en) Methods and compositions for treating cancer
EP2836482A4 (en) Compositions and methods for treating cancer
EP2890720A4 (en) Compositions and methods for treating cancer
EP2734207A4 (en) Novel compositions and methods for treating prostate cancer
EP2655334A4 (en) Compositions and methods useful for treating diseases
EP2552415A4 (en) Methods of treating cancer
SG10201500124VA (en) Methods and Compositions for Treating Cancer
EP2771341A4 (en) Novel compositions and methods for treating cancer
IL225262A0 (en) Methods and compositions for treating lung cancer
EP2688594A4 (en) Methods and compositions for the treatment of cancer
EP2419136A4 (en) Compositions and methods for treating cancer
EP2544655A4 (en) Compositions and methods for treating skin
EP2575825A4 (en) Compositions and methods for treating depression
EP2635286A4 (en) Methods for treating cancer
EP2638395A4 (en) Methods of treating cancer
EP2709614A4 (en) Pharmaceutical compositions and methods for treating cancer
IL229231A0 (en) Compositions and methods for treating cancer
HK1216854A1 (en) Compositions and methods for treating cancer
HK1183766A1 (en) Compositions and methods for treating bruises
IL225483A0 (en) Compositions and methods for treating neoplasia
SG11201400976WA (en) Methods and pharmaceutical compositions for treating cancer
HK1188566A1 (en) Composition and method for treating cancer